Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Gamma-1b Plus Voriconazole in Invasive Aspergillosis and Fungal Infections
NCT00059878Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2003
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in invasive aspergillosis (IA) and filamentous fungal infection comparing Voriconazole + Interferon gamma-1b with Voriconazole + Placebo (2 arms). Primary endpoints: Safety Profile at 12 weeks, Objective Response Rate at 12 weeks and 1 more. Started Aug 2003; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
invasive aspergillosis (IA)filamentous fungal infection
Beyond the preview
Go deeper on NCT00059878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00059878.